Reference Population for Speckle Tracking Imaging

NCT01526252 | Completed

• 1 other identifier: #2011803-01H
• Study Type: observational
• Target: 91
• Locations: 1 country
• Sites: 1

Brief Summary

The SCAR study uses a software program entitled QLAB, a proprietory program, developed by Philips Healthcare (Philips Healthcare, Andover, MA). Literature on two-dimensional speckle tracking imaging (2DSTE) is growing, but data relevant to the population in the SCAR study is minimal. Accumulation of data relevant for a population of subjects will provide a set of normal values for interpretation of 2DSTE and minimize any influences from differences in data produced from different companies. This data may also assist other researchers investigate other cardiac diseases and abnormalities.

Conditions

Left Ventricular Function

Keywords

speckle tracking echocardiography; database

Outcome Measures

Primary Outcomes (1)

• Establishment of normal values data in males and females aged 20 - 80

  1 year

Eligibility Criteria

• Age: 20 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Normal healthy males and females

You may qualify if:

• Be between the ages of 20 - 80 years at study entry
• Provide written informed consent and be able to comply with study procedures, including permission to access medical records
• Have a BMI index equal to or less than 35
• Less than 5% risk of developing coronary artery disease as determined using the Combined Diamond/Forrester and CASS data (ACC Stable CAD Guidelines)

You may not qualify if:

• Have taken cardioactive drugs within 6 months prior to examination
• These include but are not limited to beta-blockers, calcium channel blockers, and angiotensin converting enzyme inhibitors
• Currently clinically significant chronic or acute illness
• Documented cardiovascular disease
• Possess abnormal cardiac structure and function after examination with routine ECHO
• This may include valvular defects, left ventricular hypertrophy, cardiomyopathies or pericardial disease
• Documented congenital heart conditions or defects
• History of diabetes
• Be unwilling to provide voluntary consent

Sponsors & Collaborators

• Ottawa Heart Institute Research Corporation: lead

Study Sites (1)

University of Ottawa Heart Institute

Ottawa, Ontario, K1Y 4W7, Canada

Location

Study Officials

• Terrence Ruddy, MD

  Ottawa Heart Institute Research Corporation

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: January 31, 2012
• First Posted: February 3, 2012
• Study Start: December 1, 2011
• Primary Completion: July 1, 2012
• Study Completion: January 1, 2015
• Last Updated: April 24, 2017

Record last verified: 2017-04

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)